Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Investor Presentation (June 2018)
36 slides from Vivimed Labs's investor presentation, June 2018
Slide 1: Vivimed Labs Ltd Investor Presentation June 2018
Vivimed Labs Ltd / Active Pharma Branded Specialty Ingredient Formulations Chemicals Investor Presentation June 2018 1 1
Slide 2: Safe Harbor
Safe Harbor / This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vivimed Labs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securi
Slide 3: Consolidated Performance Highlights
Consolidated Performance Highlights / Revenue EBITDA Net Profit 1,258.1 246.2 85.2 1,185.7 211.3 75.4 FY17* FY18 FY17* FY18 FY17* FY18 ▪ Price pressure on some of the key raw material being sourced from China, have shown an unreasonable increase, thereby negatively impacting our margins in the API b
Slide 4: Segmental Information
Segmental Information / 46.1% 31.1% 14.3% 10.5% 451.5 1010.4 985.3 Revenue Specialty Chemicals Pharmaceuticals 200.3 FY17 FY18 FY17 FY18 EBIT Margins% Specialty Chemicals: 1. The FY17 figures also include the sales from the segments which were divested to Clariant ( India) Ltd. while the FY18 figure
Slide 5: Reducing Debt in the Company
Reducing Debt in the Company / Debt (in Rs. Crs) -229 1,006 926 777 Mar-17 Sep-17 Mar-18 Vivimed has been focused towards debt reduction and reducing the cost of funds # Consolidated Figures, as per IND AS 5
Slide 6: Soneas Acquisition: To broaden UQUIFA's offering in CDMO
Soneas Acquisition: To broaden UQUIFA’s offering in CDMO / About ‘SONEAS’ • Leading Central European custom and contract developer and Value Proposition manufacturer of fine chemicals for the pharma and other industries based in Budapest, Hungary • Broadens UQUIFA’s market offering in the CDMO space
Slide 7: Business on a Growth Track
Business on a Growth Track / Formulations API Specialty Chemicals • Joint Venture agreement with M/s • Acquisition of Soneas, to broaden • Demand in the Basic and Oxidatives Strides Shasun Ltd, to ensure full UQUIFA’s offering in CDMO dyes, showing a marked increase utilization of Alathur Plant. Exp
Slide 8: Vivimed Labs at a Glance
Vivimed Labs at a Glance / Global supplier of niche molecules and formulations across Pharmaceuticals and Specialty Chemicals Pharmaceuticals: Present across the critical components in the value chain US FDA approved world class manufacturing facilities Leveraging India based R&D for competitive adv
Slide 9: Business Divisions
Business Divisions / • Uquifa s.a. is the Spanish subsidiary of Vivimed Labs with 80 years of experience Revenue Break Up as of FY2018 having US FDA approved manufacturing units in Spain (2) and Mexico (1) • Manufactures APIs for pharmaceutical and animal health industries globally API • It has over
Slide 10: Multinational Global Platform
Multinational Global Platform / Facilities Total Pharmaceuticals– API 3 Pharmaceuticals – FDF 7 Kashipur Haridwar Specialty Chemicals - Active 1 Ingredients Total Facilities 11 Sant Celoni, Spain R&D Facilities 6 Lliçà de Vall, Spain Kolkata Global Support Offices 5 Cuernavaca, Mexico Bidar Bolarum
Slide 11: Global Clientele
Global Clientele / Preferred Supplier to the leading global brands 11
Slide 12: Transnational Experienced Management Team
Transnational Experienced Management Team / Santosh Varalwar Sandeep Varalwar Saurabh SG S. Raghunandan (Managing Director) (Executive Director, FDF) (Executive Director, Strategy (Director - Operations) & Business Development) ▪ Associated with Vivimed ▪ More than 2 decades of • First generation en
Slide 13: API Business - UQUIFA
API Business - UQUIFA / API (UQUIFA) Pharma FDF Specialty Chemicals 13
Slide 14: Consistently Delivering Excellence....
Consistently Delivering Excellence…. / FDA Approved Global Footprints Production Facilities Multi-product 3 multi- Relationship Western Diversified Clear verticals relationship product plant with leading Producer product in the with blue across pharma portfolio portfolio chip continents names Custom
Slide 15: ...Backed by API's consistency and CDMO evolution
…Backed by API’s consistency and CDMO evolution / UQUIFA by Products 4.8% API’s Consistency CDMO 40.0% • UQUIFA’s generics segment has realized material growth due to strong underlying end-market generic drug demand, price growth and new customers API 95.2% • Generics growth has also come from custo
Slide 16: Diversified Product Portfolio
Diversified Product Portfolio / Product Portfolio Main Clients UQUIFA has good volume share in the below products Bulk Generics Anti Ulcer Etofenamate Antibiotic Doxylamine Succinate Antifungal Ranitidine Antiviral Omeprazole Antihistamine Analgesic Pantoprazole Niche Generics Anti Hypertensive Quet
Slide 17: API- Growth Drivers
API- Growth Drivers / Product molecules with strong underlying demand for therapy areas: anti-ulcer, CNS and CVS • Anti-Ulcers comprise ~40% of business and the Company is focused on expanding in other therapeutic areas Favourable pricing due to competitive positioning and higher compliance reliabil
Slide 18: CDMO vertical gaining traction
CDMO vertical gaining traction / Ability to Scale-Up operations offers 05 Business volumes with competitive advantage established Clients is gaining traction 04 Better revenue stability and visibility 03 Tie-ups with innovator companies offering huge 02 potential 01 Promising product pipeline to dri
Slide 19: Industry Tailwinds
Industry Tailwinds / • High regulatory barriers, time factor and cost of validation becoming entry barriers. • Experienced players like Benefit from UQUIFA are benefitting from it High Entry Barriers ▪ Chemical skills and ability to Increasing regulatory concerns scale up can help to achieve makes U
Slide 20: Pharma FDF Business
Pharma FDF Business / Pharma FDF Specialty Chemicals 20
Slide 21: Business Overview
Business Overview / Company manufactures wide range of dosage forms which finds acceptance in regulated and pharmerging markets Key Business Segments Contract Manufacturing (CMO) Regulated Markets Pharmerging Markets • Product Type: Capsules and • Acquired US FDA approved Solid • Focused towards, me
Slide 22: Facilities Overview
Facilities Overview / Jeedimetla Hyderabad Kashipur Uttarakhand PICs/NDA/WHO-GMP • ISO 9001-2000, ISO 14001 and OHSAS 18001 approvals certifications • WHO-GMP/NAFDAC approvals Klar-sehen Jeedimetla, Hyderabad Haridwar Uttarakhand • ISO 13485 certified • ISO 9001-2000, ISO 14001 and OHSAS 18001 • CE
Slide 23: Key Strengths and Growth Drivers
Key Strengths and Growth Drivers / Strengths Growth Drivers • A dedicated team of 60 scientists working • Planning to launch formulations based on on formulation developments for USA / UQUIFA API’s in the Indian and ROW Australia / EU and India market markets • Pan India presence in Institution • De
Slide 24: Specialty Chemicals Business
Specialty Chemicals Business / Specialty Chemicals 24
Slide 25: Overview
Overview / • Manufacturing active ingredients for home care, personal care and industrial products • Product range - hair dyes, photochromic dyes, photochromic products, anti-microbials and imaging chemicals • Maintains leadership position through captive manufacturing (Bidar-Karnataka) or with othe
Slide 26: Segment Journey
Segment Journey / 2015-2017 Strategic Move • Sold a part of its home and 2010-2014 personal care business segment to Clariant (India) Ltd Customization and Diversification • Launched a new hair care • Entered new segments through 2006-2009 exclusive partnerships for product called MBB specifically f
Slide 27: Strong Customer Coverage
Strong Customer Coverage / Through Key Account Managers USA P&G, Colgate Sales & Marketing Team Direct Reach • Dedicated account managers who ensure enhanced Customer service, (KAM Approach) Customer mining & creation of new business opportunities EU P&G • Matrix structure across geographies and fun
Slide 28: Growth on Track
Growth on Track / Increasing market share from existing products New Focus Verticals Jarocol Naturals • Jarocol is a globally recognized trademark serving £ 10 billion retail market and it is growing by 5-6% year on year ▪ Cosmeceuticals: Beauty from within • Vivimed is strategically aligned with gl
Slide 29: Top Customers
Top Customers / Hair Dyes Photochromatic COSMOTEC 29
Slide 30: Vision 2020
Vision 2020 / To achieve leadership in API’s, CDMO, and FDF segments Strengthen operations across all business through continuous R&D, robust product pipeline and focus on steady growth Expand global footprints by leveraging diversified manufacturing facilities and partnership tie-ups with big pharm
Slide 31: Financial Performance
Financial Performance / API (UQUIFA) Pharma FDF Specialty Chemicals 31
Slide 32: Consolidated P&L Statement
Consolidated P&L Statement / Particulars (Rs. In Crores) Q4FY18 Q4FY17 YoY Q3FY18 QoQ FY18 FY17 YoY REVENUE 285.6 436.7 -34.6% 299.6 -4.7% 1185.7 1461.9 -18.9% Cost of Material Consumed 108.6 104.7 128.2 479.7 536.3 Employee Expenses 58.3 48.3 52.3 197.8 190.0 Other Expenses 84.9 106.5 70 296.2 333.
Slide 33: Consolidated Balance Sheet
Consolidated Balance Sheet / Particulars (Rs. Crs) 31 March 2018 31 March 2017 Particulars (Rs. Crs) 31 March 2018 31 March 2017 EQUITY AND LIABILITIES ASSETS (1) Equity (1) Non current assets (a) Equity share capital 16.5 16.2 (b) Instruments entirely equity in nature 325.2 0.0 (a) Property, Plant
Slide 34: Standalone P&L Statement
Standalone P&L Statement / Particulars (Rs. In Crores) Q4FY18 Q4FY17 YoY Q3FY18 QoQ FY18 FY17 YoY REVENUE 68.0 226.1 -69.9% 65.9 3.2% 261.4 569.8 -54.1% Cost of Material Consumed 19.9 38.1 23.9 86.4 179.9 Employee Expenses 9.1 11.8 8.8 34.1 42.2 Other Expenses 20.3 37.4 13.3 64.0 97.4 Other Comprehe
Slide 35: Standalone Balance Sheet
Standalone Balance Sheet / Particulars (Rs. Crs) 31 March 2018 31 March 2017 Particulars (Rs. Crs) 31 March 2018 31 March 2017 EQUITY AND LIABILITIES ASSETS (1) Equity (1) Non current assets (a) Equity share capital 16.5 16.2 (b) Instruments entirely equity in nature 0.0 0.0 (a) Property, Plant and
Slide 36: For further information, please contact
/ For further information, please contact: Company : Vivimed Labs Ltd. CIN:L02411KA1988PLC009465 Mr. Sunil Arab Email: Sunil.Arab@vivimedlabs.com www.vivimedlabs.com 36